News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Double that by E.o.Y $$$$$$$$$
Here’s what matters( imho)
* As of June 30, 2024, the Company had cash and cash equivalents of $87.4 million, compared to $57.4 million as of December 31, 2023. This includes net proceeds of the $50 million underwritten registered direct offering priced at-the-market on June 14, 2024.
The Company expects, based on current operational plans, that its existing cash and cash equivalents balance will enable it to fund its currently committed clinical trials, operating expenses including pre-commercial activities for setrusum-ab, and capital expenditure requirements into 2027.
This guidance does not include any potential upfront payments associated with a partnership for alvelestat or business development activity around any of the Company's non-core programs.
The Company has two rare disease product candidates, setrusumab for the treatment of osteogenesis imperfecta (Ol) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-asso-ciated lung disease (AATD-LD). The Company's partner, Ultragenyx Pharmaceutical, Inc., has completed enrollment in the Phase 3 portion of a pivotal Phase 2/3 pediatric study in young adults (5 to 25 years old) for setrusumab in Ol and in the Phase 3 study in pediatric patients (2 to <7 years old) in the first half of 2024. The partnership with Ultragenyx includes potential additional milestone payments of up to $245 million and royalties to Mereo on commercial sales in Ultragenyx territories.
Mereo has retained EU and UK commercial rights and will pay Ultragenyx royalties on commercial sales in those territories. Setrusumab has received orphan designation for osteogenesis imperfecta from the EMA and FDA, PRIME designation from the EMA and has pediatric disease designation from the FDA. Alvelestat has received U.S. Orphan Drug Designation for the treatment of AATD and Fast Track designation from the FDA.
Following results from ASTRAEUS and ATALANTa in AATD-lung disease, the Company has aligned with the FDA and the EMA on the primary endpoints for a Phase 3 pivotal study which if successful could enable full approval in both the U.S. and Europe. In addition to the rare disease programs, Mereo has two oncology products,etc…..
My best performing Bio in 2024, and will be in 25’
Only Protara (Tara) will outperform next year!!!
GLTA
MREO under $4
Here we go, $4 to be breached today??
http://archive.fast-edgar.com/20240612/AT22D22DZZ2R72ZZ2RJE2WYSQE79YZ22Z262
CJ, you still in this ticker??
Was trying to break $3.5-4ish, need some updated progress with P3 preliminary
MREO under $5
MREO 10Q due 4/3
MREO 10Q due 3/27
Fireside chat at 11:20am (est.)…stay tuned
MREO new 52 week high
AI
